Oncotelic Therapeutics, Inc.
OTLC
$0.047
$0.0024.44%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -- | -- |
| SG&A Expenses | -42.82% | -34.47% | -45.61% | -71.01% | -57.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.09% | -44.02% | -52.92% | -71.39% | -62.43% |
| Operating Income | 38.61% | 37.51% | 49.27% | 76.02% | 67.00% |
| Income Before Tax | 42.18% | 41.75% | 61.47% | 88.99% | -188.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.18% | 41.75% | 61.47% | 88.99% | -188.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.88% | -15.65% | -15.06% | -14.81% | 11.76% |
| Net Income | 43.31% | 42.76% | 62.60% | 90.72% | -182.66% |
| EBIT | 38.61% | 37.51% | 49.27% | 76.02% | 67.00% |
| EBITDA | -- | -- | 87.65% | 93.85% | 78.52% |
| EPS Basic | 45.73% | 45.05% | 63.44% | 90.38% | -179.60% |
| Normalized Basic EPS | 5.56% | 22.73% | 51.52% | 77.55% | 66.67% |
| EPS Diluted | 36.18% | 35.64% | 57.50% | 90.38% | -179.60% |
| Normalized Diluted EPS | 5.56% | 22.73% | 51.52% | 77.55% | 66.67% |
| Average Basic Shares Outstanding | 5.28% | 5.24% | -0.33% | -0.23% | 0.28% |
| Average Diluted Shares Outstanding | 5.28% | 5.24% | -0.33% | -0.23% | 0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |